[go: up one dir, main page]

DE60139907D1 - Pharmazeutische Zubereitung enthaltend Drospirenon - Google Patents

Pharmazeutische Zubereitung enthaltend Drospirenon

Info

Publication number
DE60139907D1
DE60139907D1 DE60139907T DE60139907T DE60139907D1 DE 60139907 D1 DE60139907 D1 DE 60139907D1 DE 60139907 T DE60139907 T DE 60139907T DE 60139907 T DE60139907 T DE 60139907T DE 60139907 D1 DE60139907 D1 DE 60139907D1
Authority
DE
Germany
Prior art keywords
drospirenone
composition
pharmaceutical preparation
preparation containing
further embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139907T
Other languages
English (en)
Inventor
Wolfgang Heil
Juergen Hilmann
Ralph Lipp
Rolf Schuermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60139907(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Application granted granted Critical
Publication of DE60139907D1 publication Critical patent/DE60139907D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
DE60139907T 2000-01-18 2001-01-18 Pharmazeutische Zubereitung enthaltend Drospirenon Expired - Lifetime DE60139907D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18

Publications (1)

Publication Number Publication Date
DE60139907D1 true DE60139907D1 (de) 2009-10-22

Family

ID=26071749

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60139907T Expired - Lifetime DE60139907D1 (de) 2000-01-18 2001-01-18 Pharmazeutische Zubereitung enthaltend Drospirenon
DE60113809T Expired - Lifetime DE60113809T2 (de) 2000-01-18 2001-01-18 Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60113809T Expired - Lifetime DE60113809T2 (de) 2000-01-18 2001-01-18 Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie

Country Status (30)

Country Link
EP (2) EP1257280B1 (de)
JP (2) JP5128743B2 (de)
KR (2) KR100747965B1 (de)
CN (2) CN1395488A (de)
AT (2) ATE442147T1 (de)
AU (3) AU2541301A (de)
BG (1) BG65849B1 (de)
BR (1) BR0107683A (de)
CA (1) CA2394165C (de)
CY (1) CY1109567T1 (de)
CZ (1) CZ20022411A3 (de)
DE (2) DE60139907D1 (de)
DK (2) DK1257280T3 (de)
EE (1) EE05533B1 (de)
ES (2) ES2332226T3 (de)
HK (1) HK1047248B (de)
HU (1) HUP0204291A3 (de)
IL (3) IL150775A0 (de)
ME (1) ME00292B (de)
MX (1) MXPA02006613A (de)
NO (1) NO335570B1 (de)
NZ (1) NZ520630A (de)
PL (1) PL201878B1 (de)
PT (1) PT1611892E (de)
RS (1) RS52149B (de)
RU (2) RU2275198C2 (de)
SI (2) SI1611892T1 (de)
SK (2) SK287719B6 (de)
WO (1) WO2001052857A1 (de)
ZA (2) ZA200206551B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60006692T2 (de) * 1999-08-31 2004-09-23 Schering Ag Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel
EP1216713A1 (de) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Zusammensetzungen von Estrogen-Zyklodextrin Komplexe
EP1406634A1 (de) 2001-07-13 2004-04-14 Schering Aktiengesellschaft Kombination von drospirenon und estrogensulphamate-derivaten als hormon-replacement-therapie
JP2005519961A (ja) * 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法
RU2373940C2 (ru) * 2002-04-26 2009-11-27 "Байер Шеринг Фарма Акциенгезельшафт" Лечение гипертензии у женщин, подвергающихся гормонзаместительной терапии
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
WO2004041289A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
SI1748756T1 (sl) * 2004-03-10 2009-10-31 Bayer Schering Pharma Ag Sestavki, ki obsegajo molekularno dispergiran drospirenon
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20090181075A1 (en) * 2005-07-15 2009-07-16 Gordon Ryan D Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
WO2011128336A1 (en) * 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Very low-dosed solid oral dosage forms for hrt
JP5852639B2 (ja) * 2010-04-15 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ｈｒｔのための低用量固体経口投与形態
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CN103957921A (zh) 2011-11-04 2014-07-30 拜耳医药股份有限公司 18-甲基-6，7-亚甲基-3-氧代-17-孕甾-4-烯-21，17β-碳内酯、包含所述化合物的药物制剂及其在治疗子宫内膜异位症中的用途
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
SMT202200102T1 (it) 2015-06-18 2022-05-12 Estetra Srl Unità di dosaggio orodispersibile contenente un componente di estetrolo
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JP7154616B2 (ja) * 2017-06-01 2022-10-18 ネクシオン バイオテック カンパニー リミテッド 骨関連疾患の予防または治療のための薬学組成物
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
CN118356456A (zh) * 2024-04-17 2024-07-19 且安生物科技有限责任公司 一种抗炎护巢草本提取制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
AU3961697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
KR100518102B1 (ko) * 1996-07-26 2005-10-04 와이어쓰 프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
DE60006692T2 (de) * 1999-08-31 2004-09-23 Schering Ag Pharmazeutische kombination von ethinylestradiol und drospirenone als empfängnisverhütendes mittel

Also Published As

Publication number Publication date
EP1611892A3 (de) 2006-02-01
RU2275198C2 (ru) 2006-04-27
EP1257280A1 (de) 2002-11-20
JP5563227B2 (ja) 2014-07-30
CA2394165C (en) 2010-04-13
RU2002122113A (ru) 2004-03-10
ME00292B (me) 2011-05-10
AU2541301A (en) 2001-07-31
JP5128743B2 (ja) 2013-01-23
IL150775A0 (en) 2003-02-12
HUP0204291A2 (hu) 2003-04-28
EP1611892B1 (de) 2009-09-09
KR20020088066A (ko) 2002-11-25
HK1082433A1 (en) 2006-06-09
BR0107683A (pt) 2002-11-12
MXPA02006613A (es) 2003-10-15
ES2332226T3 (es) 2010-01-29
SI1611892T1 (sl) 2010-01-29
IL191131A (en) 2010-12-30
PL201878B1 (pl) 2009-05-29
ATE305789T1 (de) 2005-10-15
RU2402331C2 (ru) 2010-10-27
NO20022966D0 (no) 2002-06-20
DK1257280T3 (da) 2005-12-12
DK1611892T3 (da) 2009-11-02
CA2394165A1 (en) 2001-07-26
PT1611892E (pt) 2009-11-20
SI1257280T1 (sl) 2006-02-28
EP1611892A2 (de) 2006-01-04
YU54602A (sh) 2006-01-16
BG65849B1 (bg) 2010-03-31
RU2005140938A (ru) 2007-07-10
JP2003520239A (ja) 2003-07-02
SK287719B6 (en) 2011-07-06
IL150775A (en) 2008-08-07
ZA200206551B (en) 2006-04-29
KR20070051956A (ko) 2007-05-18
WO2001052857A1 (en) 2001-07-26
EE05533B1 (et) 2012-04-16
SK10322002A3 (sk) 2003-03-04
SK288129B6 (sk) 2013-10-02
DE60113809D1 (de) 2006-02-16
ATE442147T1 (de) 2009-09-15
CZ20022411A3 (cs) 2003-02-12
ES2247054T3 (es) 2006-03-01
EE200200401A (et) 2003-10-15
HK1047248B (en) 2005-12-30
KR100747965B1 (ko) 2007-08-08
RS52149B (sr) 2012-08-31
CN101934078A (zh) 2011-01-05
EP1257280B1 (de) 2005-10-05
CN1395488A (zh) 2003-02-05
IL191131A0 (en) 2008-11-03
HUP0204291A3 (en) 2003-05-28
DE60113809T2 (de) 2006-06-22
AU2005209600B2 (en) 2008-08-07
JP2009120615A (ja) 2009-06-04
PL356987A1 (en) 2004-07-12
NZ520630A (en) 2004-09-24
MEP38008A (en) 2011-02-10
KR100913910B1 (ko) 2009-08-26
CY1109567T1 (el) 2014-08-13
NO335570B1 (no) 2014-12-29
AU2001225413B2 (en) 2005-06-23
HK1047248A1 (en) 2003-02-14
BG106915A (bg) 2003-04-30
AU2005209600A1 (en) 2005-09-29
NO20022966L (no) 2002-09-18
ZA200601285B (en) 2008-01-08

Similar Documents

Publication Publication Date Title
DE60139907D1 (de) Pharmazeutische Zubereitung enthaltend Drospirenon
CA2294337A1 (en) Preparation of pharmaceutical compositions
EP1598069A3 (de) Pharmazeutische Kombination von Ethinylestradiol und Drospirenon als empfängnisverhütendes Mittel
YU58902A (sh) Oralne formulacije opijatnog agonista otporne na mehaničke, termičke i/ili hemijske promene fizičkih osobina doznog oblika
DE69627253D1 (de) Fenofibrathaltige neue galenische Arzneizusammensetzungen und ihre Verwendung
IL157963A0 (en) Hsa-free formulations of interferon-beta
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
CA2338358A1 (en) Compounds and compositions for delivering active agents
WO2003013433A3 (en) Sequestered antagonist formulations
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
GB2391471B (en) Pharmaceutical compositions
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
GB2334446B (en) Aqueous compositions compromising a lipid and a lanolin-derived surfactant,and their use
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
AU2624499A (en) Oral compositions at low dosage of cytotoxic proteins
EP0530016A3 (de) Piperidinderivat und dieses enthaltende pharmazeutische Zubereitung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition